Cancers, Vol. 11, Pages 11: Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials

In conclusion, 96.5% of patients with hematologic malignancies have adequate tissue for comprehensive genomic profiling. Most patients had unique molecular signatures, and 75% had alterations that may be pharmacologically tractable with gene- or immune-targeted agents.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research

Related Links:

Publication date: Available online 24 September 2020Source: Journal of Theoretical BiologyAuthor(s): Roberta Coletti, Andrea Pugliese, Luca Marchetti
Source: Journal of Theoretical Biology - Category: Biology Source Type: research
Publication date: Available online 24 September 2020Source: Advances in Biological RegulationAuthor(s): Nilufar Rahimova, Mariana Cooke, Suli Zhang, Martin J. Baker, Marcelo G. Kazanietz
Source: Advances in Biological Regulation - Category: Biology Source Type: research
Publication date: Available online 24 September 2020Source: Biochimica et Biophysica Acta (BBA) - BiomembranesAuthor(s): Aurélie H. Benfield, Sira Defaus, Nicole Lawrence, Stephanie Chaousis, Nicholas Condon, Olivier Cheneval, Yen-Hua Huang, Lai Yue Chan, David Andreu, David J. Craik, Sónia Troeira Henriques
Source: Biochimica et Biophysica Acta (BBA) Biomembranes - Category: Biochemistry Source Type: research
Abstract Endometrial cancer (EC) harboring heterozygous POLE proofreading inactivating mutations (POLE-exo*) is associated with an increased number of somatic mutations that result in a distinctive anti-tumor immune response. However, the consequences of such POLE mutations in the context of the missing wild-type allele have not yet been described in endometrial tumors. A 72-year-old woman harboring a germline monoallelic frameshift mutation (p.Pro269fsTer26) in POLE was diagnosed with an EC having a somatic heterozygous mutation in the exonuclease domain of POLE (S459F). Targeted gene sequencing revealed an ultramutated p...
Source: Genetics and Molecular Biology - Category: Genetics & Stem Cells Source Type: research
CONCLUSION: The study identified both a high prevalence of xerostomia regardless of the chemotherapy used and the need to create protocols to improve the quality of life of these patients. PMID: 32965427 [PubMed - in process]
Source: Revista Brasileira de Enfermagem - Category: Nursing Authors: Tags: Rev Bras Enferm Source Type: research
Publication date: Available online 25 September 2020Source: Actas Urológicas Españolas (English Edition)Author(s): L. Polanco Pujol, F. Herranz Amo, J. Caño Velasco, M. Moralejo Garate, D. Subirá Rios, G. Barbas Bernardos, J. Mayor de Castro, J. Aragón Chamizo, A. Husilllos Alonso, C. Hernández Fernández
Source: Actas Urologicas Espanolas - Category: Urology & Nephrology Source Type: research
Publication date: Available online 24 September 2020Source: European UrologyAuthor(s): Vignesh T. Packiam, Bimal Bhindi
Source: European Urology - Category: Urology & Nephrology Source Type: research
Publication date: Available online 24 September 2020Source: European UrologyAuthor(s): Marcus Cumberbatch, Benjamin Condon, Nathan Lawrentschuk, Declan G. Murphy
Source: European Urology - Category: Urology & Nephrology Source Type: research
Publication date: Available online 24 September 2020Source: European UrologyAuthor(s): Trevor J. Royce, Andrew Z. Wang, Ronald C. Chen
Source: European Urology - Category: Urology & Nephrology Source Type: research
Best known as a cell cycle regulator, p53 signaling mediates pro and anti-cancer immune responses as well
Source: The Scientist - Category: Science Tags: Sponsored Infographics Source Type: news
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Clinical Trials | Genetics | Hematology | Leukemia | Lymphoma | Myelodysplastic Syndrome | Myeloma | Myeloproliferative Disorders | Non-Hodgkin's Lymphoma